Nitroxyl radicals for labeling of conventional therapeutics and noninvasive magnetic resonance imaging of their permeability for blood-brain barrier: relationship between structure, blood clearance, and mri signal dynamic in the brain

Molecular Pharmaceutics

Volumn 6, Issue 2, 2009, Pages 504-512

  Zhelev, Zhivko ^a   Bakalova, Rumiana ^a,c   Aoki, Ichio ^a   Matsumoto, Ken Ichiro ^b   Gadjeva, Veselina ^c   Anzai, Kazunori ^b   Kanno, Iwao ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b Department of Chemistry and Biochemistry ^*  (Bulgaria)

^c TRAKIA UNIVERSITY   (Bulgaria)

Author keywords

Blood brain barrier permeability; Electron paramagnetic resonance imaging; Lomustine; Magnetic resonance imaging; Nitroxyl radicals

Indexed keywords

[1 CHLOROETHYL 3 [4 GLYCINE (2,2,6,6 TETRAMETHYLPIPERIDINE 1 OXYL)] 1 NITROSOUREA]; [1 ETHYL 3 [4 (2,2,6,6 TETRAMETHYLPIPERIDINE 1 OXYL)] 1 NITROSOUREA]; LOMUSTINE; NITROSOUREA DERIVATIVE; TEMPOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CELL PERMEABILIZATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SYNTHESIS; DRUG TRANSPORT; ELECTRON SPIN RESONANCE; HYDROPHOBICITY; LD 50; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; SPIN LABELING; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD FLOW VELOCITY; BLOOD-BRAIN BARRIER; BRAIN; CYCLIC N-OXIDES; ELECTRON SPIN RESONANCE SPECTROSCOPY; LOMUSTINE; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C57BL; NITROGEN OXIDES; SPIN LABELS; TISSUE DISTRIBUTION;

EID: 64649089593     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp800175k     Document Type: Article

References (35)

1. Griffeth, L. K.; Rosen, G. M.; Rauckman, E. J.; Drayer, B. P. Pharmacokinetics of nitroxide NMR contrast agents. Invest. Radiol. 1984, 19, 553-562.
2. Keana, J. F.; Pou, S.; Rosen, G. M. Nitroxides as potential contrast enhancing agents for MRI application: influence of structure on the rate of reduction by rat hepatocytes, whole liver homogenate, subcellular fractions, and ascorbate. Magn. Reson. Med. 1987, 5, 525-536.
3. Valgimigli, L.; Pedulli, G. F.; Paolini, M. Measurement of oxidative stress by EPR radical-probe technique. Free Radical Biol. Med. 2001, 31, 708-716.
4. Utsumi, H.; Yamada, K. In vivo electron spin resonance-computed tomography/nitroxyl probe technique for non-invasive analysis of oxidative injuries. Arch. Biochem. Biophys. 2003, 416, 1-8.
5. Takeshita, K.; Ozawa, T. Recent progress in in vivo ESR spectroscopy. J. Radiat. Res. (Tokyo) 2004, 45, 373-384.
6. Soule, B. P.; Hyodo, F.; Matsumoto, K.; Simone, N. L.; Cook, J. A.; Krishna, M. C.; Mitchell, J. B. Therapeutic and clinical applications of nitroxide compounds. Antioxid. Redox Signaling 2007, 9, 1731-1743.
7. Afzal, V.; Brasch, R. C.; Nitecki, D. E.; Wolff, S. Nitroxyl spin label contrast enhancers for magnetic resonance imaging. Studies of acute toxicity and mutagenesis. Invest. Radiol. 1984, 19, 549552.
8. Matsumoto, K.; Hyodo, F.; Matsumoto, A.; Koretsky, A. P.; Sowers, A. L.; Mitchell, J. B.; Krishna, M. C. High-resolution mapping of tumor redox status by MRI using nitroxides as redox- sensitive contrast agents. Clin. Cancer Res. 2006, 12, 2455-2462.
9. Hyodo, F.; Matsumoto, K.; Matsumoto, A.; Mitchel, J. B.; Krishna, M. C. Probing the intracellular redox status of tumors with MRI and redox-sensitive contrast agents. Cancer Res. 2006, 66, 99219928.
10. Hyodo, F.; Matsumoto, K.; Matsumoto, A.; Mitchel, J. B.; Krishna, M. C. Probing the intracellular redox status of tumors with MRI and redox-sensitive contrast agents. Cancer Res. 2006, 66, 99219928.
11. Hyodo, F.; Chuang, K.-H.; Goloshevsky, A. G.; Sulima, A.; Griffiths, G. L.; Mitchell, J. B.; Koretsky, A. P.; Krishna, M. C. Brain redox imaging using blood-brain barrier-permeable nitroxide MRI contrast agent. J. Cereb. Blood Flow Metab. 2008, 1-10.
12. Myiake, M.; Shen, J.; Liu, S.; Shi, H.; Liu, W.; Yuan, Z.; Pritchard, A.; Kao, J. P. Y.; Liu, K. J.; Rosen, G. M. Acetoxymethoxycar- bonyl nitroxides as EPR proimaging agents to measure O2 levels in mouse brain: A pharmacokinetic and pharmacodynamic study. J. Pharmacol. Exp. Ther. 2006, 318, 1187-1193.
13. Shen, J.; Liu, S.; Miyake, M.; Liu, W.; Pritchard, A.; Kao, J. P. Y.; Rosen, G. M.; Tong, Y.; Liu, K. J. Use of 3-acetoxymethoxy- carbonyl-2,2,5,5- tetramethyl-1-pyrroh'dinyloxyl as an EPR oxim- etry probe: Potential for in vivo measurement of tissue oxygen- ation in mouse brain. Magn. Reson. Med. 2006, 55, 1433-1440.
14. Sano, H.; Naruse, M.; Matsumoto, K.; Oi, T.; Utsumi, H. A new nitroyxl-probe with high retention in the brain and its application for brain imaging. Free Radical Biol. Med. 2000, 28, 959-969.
15. Anzai, K.; Saito, K.; Takeshita, K.; Takahashi, S.; Miyazaki, H.; Shoji, H.; Lee, M. C.; Masumizu, T.; Ozawa, T. Assessment of ESR-CT imaging by comparison with autoradiography for the distribution of a blood-brain-barrier permeable spin probe, MC- PROXYL, to rodent brain. Magn. Reson. Imaging 2003, 21, 765772.
16. Cotrim, A. P.; Hyodo, F.; Matsumoto, K.; Sowers, A. L.; Cook, J. A.; Baum, B. J.; Krishna, M. C.; Mitchell, J. B. Differential radiation protection of salivary glands versus tumor by tempol with accompanying tissue assessment of tempol by magnetic resonance imaging. Clin. Cancer Res. 2007, 13, 4928-4933.
17. Zhang, L.; Zhu, H.; Oprea, T. I.; Golbraikh, A.; Tropsha, A. QSAR modeling of the blood-brain barrier permeability for diverse organic compounds. Pharm. Res. 2008, 25, 1902-1914.
18. Shen, D. D.; Artru, A. A.; Adkison, K. K. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv. Drug Delivery Rev. 2004, 56, 1825-1857.
19. Pan, D.; Iyer, M.; Liu, J.; Li, Y.; Hopfinger, A. J. Constructing optimum blood brain barrier QSAR models using a combination of 4D-molecular similarity measures and cluster analysis. J. Chem. Inf. Comput. Sci. 2004, 44, 2083-2098.
20. Dash, A. K.; Elmquist, W. F. Separation methods that are capable of revealing blood-brain barrier permeability. J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2003, 797, 241-254.
21. Gumbleton, M.; Audus, K. L. Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J. Pharm. Sci. 2001, 90, 1681-1698.
22. Killian, D. M.; Gharat, L.; Chikhale, P. J. Modulating blood-brain barrier interactions of amino acid-based anticancer agents. Drug Delivery 2000, 7, 21-25.
23. Josserand, V.; Pélerin, H.; de Bruin, B.; Jego, B.; Kuhnast, B.; Hinnen, F.; Ducongé, F.; Boisgard, R.; Beuvon, F.; Chassoux, F.; Daumas-Duport, C.; Ezan, E.; Dollé, F.; Mabondzo, A.; Tavitian, B. Evaluation of drug penetration into the brain: a double study by in vivo imaging with positron emission tomography and using an in vitro model of the human blood-brain barrier. J. Pharmacol. Exp. Ther. 2006, 316, 79-86.
24. Abbott, N. J.; Chugani, D. C.; Zaharchuk, G.; Rosen, B. R.; Lo, E. H. Delivery of imaging agents into brain. Adv. Drug Delivery Rev. 1999, 37, 253-277.
25. Weissleder, R.; Mahmood, U. Molecular imaging. Radiology 2001, 219, 316-333.
26. Taphoorn, M. J. B.; Van den Bent, M. J.; Mauer, M. E. L.; Coens, C.; Delattre, J.-Y.; Brandes, A. A.; Smitt, P. A. E.; Besrnsen, H. J. J. A.; Frenay, M.; Tijssen, C. C.; Lacombe, D.; Allgeier, A.; Bottomley, A. Health-related quality of life in patients treated for anaplastic oligodendroma with adjuvant chemotherapy: Results of a European Organisation for Research and Treatment of Cancer Randomized Clinical Trial. J. Clin. Oncol. 2007, 25, 5723-5730.
27. Bodor, N.; Buchwald, P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv. Drug Delivery Rev. 1999, 36, 229-254.
28. Gadjeva, V. Structure-based design of nitrosoureas containing tyrosine derivatives as potential antimelanoma agents. Eur. J. Med. Chem. 2002, 37, 295-300.
29. Zheleva, A.; Gadjeva, V. Spin labelled nitrosoureas and triazenes and their non-labelled clinically used analogues-- a comparative study on their physicochemical properties and antimelanomic effects. Int. J. Pharmacol. 2001, 212, 257-266.
30. Hayashi, H.; Iwasaki, T.; Onodera, Y.; Nagase, T.; Itabashi, O. Tohoku Kogyo Gijitsu Shikenjo Houkoku 1992, 29,33.
31. Matsumoto, K.; Krishna, M. C.; Mitchell, J. B. Novel pharma- cokinetic measurement using electron paramagnetic resonance spectroscopy and simulation of in vivo decay of various nitroxyl spin probes in mouse blood. J. Pharmacol. Exp. Ther. 2004, 310, 1076-1083.
32. Matsumoto, K.; Yakumaru, H.; Narazaki, M.; Nakagawa, H.; Anzai, K.; Ikehira, H.; Ikota, N. Modification of nitroxyl contrast agents with multiple spins and their proton T1 relaxivity. Magn. Reson. Imaging 2008, 26, 117-121.
33. Metz, J. M.; Smith, D.; Mick, R.; Lustig, R.; Mitchell, J.; Cherakuri, M.; Glatstein, E.; Hahn, S. M. A phase I study of topical Tempol for the prevention of alopecia induced by whole brain radiotherapy. Clin. Cancer Res. 2004, 10, 6411-6417.
34. Ravizza, R.; Cereda, E.; Monti, E.; Gariboldi, M. B. The piperidine nitroxide Tempol potentiates the cytotoxic effects of Temozolo- mide in human glioblastoma cells. Int. J. Oncol. 2004, 25, 18171822.
35. Hahn, S. M.; Wilson, L.; Krishna, C. M.; Liebmann, J.; DeGraff, W.; Gamson, J.; Amuni, A.; Venzon, S.; Mitchell, J. Identification of nitroxide radioprotectors. Radiat. Res. 1992, 123, 87-93.